Paratek Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.6M
Doctors Paid
24,962
Transactions
87,450
2024 Total
$3.3M
Payment Breakdown by Category
Research$8.9M (57.1%)
Food & Beverage$2.0M (12.8%)
Consulting$1.4M (9.1%)
Travel$873,431 (5.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.9M | 847 | 57.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 1,242 | 13.5% |
| Food and Beverage | $2.0M | 82,281 | 12.8% |
| Consulting Fee | $1.4M | 398 | 9.1% |
| Travel and Lodging | $873,431 | 1,854 | 5.6% |
| Honoraria | $207,640 | 109 | 1.3% |
| Grant | $45,000 | 2 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $18,520 | 14 | 0.1% |
| Education | $17,544 | 692 | 0.1% |
| Gift | $948.44 | 7 | 0.0% |
| Entertainment | $706.87 | 4 | 0.0% |
Payments by Type
Research
$8.9M
847 transactions
General
$6.7M
86,603 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex | $2.3M | 1 | 466 |
| Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections | $942,883 | 0 | 9 |
| Omadacycline versus standard-of-care oral antibiotic treatment for bone and joint infections an open-label non-inferiority randomized controlled trial | $784,199 | 0 | 2 |
| Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: an Open-Label, Non-Inferiority, Randomized, Controlled Trial | $761,352 | 0 | 2 |
| A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP) | $691,200 | 0 | 98 |
| Omadacycline versus standard-of-care oral antibiotic treatment for bone and joint infections: an open-label, non-inferiority, randomized, controlled trial | $518,463 | 0 | 2 |
| Ph. 1 study to evaluate safety, tolerability & PK of 2 oral OMC formulations | $513,923 | 0 | 4 |
| Comparison of Omadacycline Pharmacokinetics and Soft-Tissue Penetration in Diabetic Patients with Wound Infections versus Healthy Volunteers via In Vivo Microdialysis | $287,862 | 0 | 5 |
| A Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects with Suspected or Confirmed Bacterial Infections | $251,693 | 0 | 68 |
| A RANDOMIZED, DOUBLE-BLINDED, ADAPTIVE PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL OMADACYCLINE AND ORAL NITROFURANTOIN IN THE TREATMENT OF FEMALE ADULTS WITH CYSTITIS | $191,611 | 0 | 50 |
| A Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects with Suspected or Confirmed Bacterial InfectionsA Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects with Suspected or Confirmed Bacterial Infections | $190,754 | 0 | 60 |
| Development of Omadacycline for Treatment of pulmonary Mycobacterium avium | $167,881 | 0 | 3 |
| Pharmacokinetics of Omadacycline in Patients with Cystic Fibrosis | $158,259 | 0 | 2 |
| Assessment of Activity of Omadacycline Against Resistant Enterococcal Strains (van-S, van-R, tet-R) in a Murine Peritonitis Model | $137,952 | 0 | 2 |
| A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus complex | $132,967 | 0 | 22 |
| Antibiotic failure among CABP and ABSSSI outpatients: A single-center retrospective and quality improvement study | $102,840 | 0 | 3 |
| Real-World Open-Label, Single-Center Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Omadacycline | $88,258 | 0 | 1 |
| In Vitro Activity of Omadacycline Against Clinical Isolates of Nocardia | $71,370 | 0 | 4 |
| Activity of Omadacycline in Methicillin-Resistant Staphylococcus aureus Osteomyelitis | $70,620 | 0 | 2 |
| MIC Testing on Retrospectively Collected Isolates | $69,496 | 0 | 2 |
| Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis | $64,876 | 0 | 4 |
| Emerging S. aureus antimicrobial resistance and current prescribing practices for patients presenting to US Emergency Departments with a purulent skin and soft tissue infection | $46,704 | 0 | 1 |
| Antibiotic Susceptibility of Clostridioides difficile to Omadacycline and Comparator Antibiotics | $41,600 | 0 | 1 |
| Activity of omadacycline against minocycline-susceptible and -resistant Acinetobacter baumannii | $35,522 | 0 | 2 |
| EVALUATING THE IN VITRO ACTIVITITY OF OMADACYCLINE AGAINST CORYNEBACTERIUM SPECIES | $17,449 | 0 | 1 |
| Activity of omadacycline against minocycline-susceptible and ?resistant Acinetobacter baumannii | $15,223 | 0 | 1 |
| Activity of Omadacycline in Methicillin-resistant Staphylococcus aureus | $15,000 | 0 | 1 |
| Comparison of In vitro Susceptibility of Omadacycline with Tigecycline, Minocycline, Doxycycline and Other Comparator Antimicrobials Against Isolates of Nontuberculous Mycobacteria | $13,121 | 0 | 1 |
| Omadacycline Susceptibilities of Organisms of Interest | $12,730 | 0 | 1 |
| Omadacycline in tuberculosis mouse models | $10,473 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Andrew Dold, D.o, D.O | Infectious Disease | Dacula, GA | $433,595 | $0 |
| Dr. David Wu, M.d, M.D | Infectious Disease | West Chester, PA | $403,723 | $0 |
| Dr. Timothy Franson, M.d, M.D | Infectious Disease | Zionsville, IN | $301,582 | $0 |
| Dr. Warren Joseph, Dpm, DPM | Primary Podiatric Medicine | Phoenix, AZ | $266,775 | $0 |
| Hector Brunet Rodriguez, Md, MD | Student in an Organized Health Care Education/Training Program | Shreveport, LA | $263,692 | $0 |
| Yoav Golan, M.d, M.D | Infectious Disease | Boston, MA | $251,886 | $0</ |